Could this East Bay generic drug maker have the urge to merge?
A rumored merger including an East Bay drug company — a major player in the generic drug market — makes sense, an analyst says, but only after looking at a potential $100 million in cuts.
Impax Laboratories Inc. (NASDAQ: IPXL) of Hayward is in talks to merge with privately held Amneal Pharmaceuticals LLC, Reuters and the Wall Street Journal repo rted. The deal would value Impax at $2 billion or more.
The possibility of a deal comes as the generic drug business further consolidates in the face…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Health Management